Lipocine announces financial results for the first quarter ended march 31, 2024

Salt lake city , may 9, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company, today announced financial results for the first quarter ended march 31, 2024 and provided a corporate update. lpcn 1154 for postpartum depression in may 2024, dosing of subjects was completed in the pivotal pharmacokinetic (pk) study designed to support a new drug application (nda) for lpcn 1154.
LPCN Ratings Summary
LPCN Quant Ranking